SynthesisPediatric cardiology2023
Longitudinal Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children: A Systematic Review and Meta-Analysis.
Synthesis in Pediatric cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Post-MIS-C cardiovascular outcomes: a systematic review.European journal of pediatrics · 2026Pooled it
- In-hospital unfavorable outcomes of MIS-C during 2020-2022: a systematic review.European journal of pediatrics · 2024Pooled it
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches.Annals of medicine · 2026Review
- Post-COVID Multisystem Inflammatory Syndrome in Children with Kawasaki-like Features: A Scoping Review of Middle Eastern Evidence.Medicina (Kaunas, Lithuania) · 2026Article
- Tracking the soluble biomarkers of MIS-C and their association with clinical parameters and severity.Pediatric research · 2026Article
- Comparison of presentation, treatment and follow-up outcomes in first and second wave cohorts of multisystem inflammatory syndrome in children.Frontiers in pediatrics · 2026Article
- Longitudinal functional and neuropsychological 2-year follow-up after intensive care admission for multisystem inflammatory syndrome in children.European journal of pediatrics · 2025Article
- Spectrum of Coronary Artery Involvement With Multisystem Inflammatory Syndrome in Children Versus Kawasaki Disease.Journal of the American Heart Association · 2025Article
- Coronary artery dilation in children with MIS-C: prevalence, risk factor, and progression.European journal of pediatrics · 2025Article
- Six-Month Outcomes in the Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children Study.JAMA pediatrics · 2025Article
- 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.Circulation · 2025Review
- An Update on Multi-System Inflammatory Syndrome in Children.Current rheumatology reports · 2025Review
- Comparison of Cardiac Findings in Pediatric Patients with Multisystem Inflammatory Syndrome in Children Associated with COVID-19.Sisli Etfal Hastanesi tip bulteni · 2025Article
- Advancing multidisciplinary management of pediatric hyperinflammatory disorders.Frontiers in pediatrics · 2025Review
- Cardiovascular abnormalities in multisystem inflammatory syndrome in children related to COVID-19.Frontiers in pediatrics · 2025Review
- Multidimensional 1-Year Outcomes After Intensive Care Admission for Multisystem Inflammatory Syndrome in Children.Critical care explorations · 2025Article
- Long-term health outcome and quality of life in children with multisystem inflammatory syndrome: findings from multidisciplinary follow-up at an Italian tertiary-care paediatric hospital.European journal of pediatrics · 2024Article
- COVID-19-Associated Multisystem Inflammatory Syndrome in Children and Cardiovascular Autonomic Control: A Prospective Cohort Study Nine Months after SARS-CoV-2 Infection.Journal of clinical medicine · 2024Article
- Postacute Sequelae of SARS-CoV-2 in Children.Pediatrics · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a paucity of longitudinal data on cardiac outcomes in multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. We aimed to investigate the longitudinal cardiovascular outcomes in MIS-C. PubMed and EMBASE were searched through May 2022. Observational studies were included, reporting mid-term (≥ 3 months) outcomes in children (aged < 21) with MIS-C. Data were extracted by two researchers. Longitudinal outcomes were synthesized by a one-group meta-analysis using a random-effects model. Eleven studies with a follow-up period (3 months to 1 year) were identified, including 547 MIS-C patients. The mortality was 2.5% (95% CI 1.3-4.9). The majority of left ventricular (LV) systolic dysfunction present in 46.8% (95% CI 32.7-61.3) in the acute phase resolved by 3 months, and the prevalence of LV systolic dysfunction was 1.7% (95% CI 0.5-5.7) and 2.1% (95% CI 0.8-5.4) at 3 month and 6 month follow-up, respectively. Additionally, the persistent LV systolic dysfunction in the small population was mild. However, coronary abnormalities such as coronary artery dilatation or aneurysms, seen in 23.7% (95% CI 17.7-31.1) at baseline, persisted in 4.7% (95% CI 1.5-14.3) at 3 months and 5.2% (95% CI 3.0-8.9) at 6 months. Mitral regurgitation (MR), which was observed in 56.6% (95% CI 27.7-81.6) at baseline, also persisted in 7.5% at 6 months. In conclusion, our study demonstrated largely favorable cardiac outcomes, suggesting resolution of LV systolic dysfunction in the majority of cases. However, coronary abnormalities and MR persisted in a subset of patients at mid-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.